State of the Clinical Trials Industry

Similar documents
SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES

Agenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015

Good Clinical Practice (GCP) & Clinical Trial Registries

US FDA: CMC Issues for INDs

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement

Rules of Human Experimentation

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?

Mark D. Kramer, RAC Regulatory Strategies, Inc.

Expanded Access (including Emergency Use & Humanitarian Use Devices)

Volunteering for Clinical Trials

THE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE

REGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts

Medidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer

Incentives and Regulatory Considerations in Orphan Drug/Medical Device Development - Situation in Japan -

WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT

GOOD CLINICAL PRACTICE (GCP) Series Catalog

Recruitment Innovation Initiative

Office for Human Subject Protection. University of Rochester

The Drug Development Process and Design of Clinical Trials

Supply of IND Agents to Multi-center trials by Skilled Academic Sites

Applicability of US Regulations to Canadian Research

1 The Clinical Research Coordinator (CRC)... 1

Introduction to Clinical Research

Update on Current FDA Policies and Priorities

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents

Regulatory Considerations and Trends Europe and the U.S.

CDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA

Definitions and Acronyms

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

The In Vitro Diagnostic CRO

PREVIEW. Benchmarking European Investigator Payments Industry Standard Research

The Economics of New Drug Development: Costs, Risks, and Returns

Investigator-Initiated INDs

Establishment of Clinical Trial Infrastructure

Regulatory Affairs - CPS (RGA)

Utilizing Innovative Statistical Methods. Discussion Guide

OCTC 2012 CRO Selection

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

FDA > CDRH > CFR Title 21 Database Search

Compliance Department RESEARCH COMPLIANCE MEMORANDUM

The Research Services Organization (RSO) of the Academic Health Center

POLICY AND PROCEDURE MANUAL

Pharmacovigilance and the Generic Industry

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees

Recommendations for Strengthening the Investigator Site Community

Center for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review.

Streamlining IRB Procedures for Expanded Access

Standard Operating Procedures Guidelines for Good Clinical Practice

WCG ACADEMY COURSE OVERVIEW

Managing Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD

Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015

Lessons learned: NCI s FLT F-18 IND and F-18 NaF NDA. Paula M. Jacobs, Ph.D. Deputy Associate Director, DCTD. NCI Cancer Imaging Program

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical

LOINC in Regulated Clinical Research a Lab LOINC Steeringg Committee Meeting 08 June 2017

Topics. Safety First Initiative. Drug Safety Communications DRUG SAFETY INITIATIVES AT THE FOOD AND DRUG ADMINISTRATION

Expanded Access and the Individual Patient IND

April 13, Background

RE: Docket No. FDA 2017 N 0041: Agency Information Collection Activities; Proposed Collection; Comment Request; Safety Assurance Case

Second Quarter 2017 Earnings Teleconference. August 1, 2017

The Intersection of Genomics Research and the IDE Regulation

Trends In Health Care R&D And Technology Innovation

PDUFA VI Public Meeting Remarks of Cynthia A. Bens Alliance for Aging Research. August 15, 2016

What is an Investigational Drug? 21CFR312.3(b)

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

CLINICAL TRIALS AND MARKET RESEARCH

1 st Quarter 2007 Earnings. April 19, 2007

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use

Pharma R&D and Patents support Health Care & Economy

FDA Advisory Committee Trends Since FDASIA

FDA approval of emergency expanded access use may be requested by telephone, facsimile, or other means of electronic communications.

Insights into the Rare Disease Drug Approval Landscape: Trends and Current Development

Activities of the Korean Association of the Institutions Review Boards (KAIRB) in the year of Korea

The Situation of Investigator Initiated Trials in Europe. Dr.N.Gökbuget

GxP Auditing, Remediation, and Staff Augmentation

Drug Development Services

Advanced Issues in Commercial Compliance. Tenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum November 11, 2009

Report from the Paediatric Committee on its first anniversary

Document Reuse: Theory and Practice

CRO partner in Rx/CDx Co-Development

NBER WORKING PAPER SERIES BLACK BOX WARNINGS AND DRUG SAFETY: EXAMINING THE DETERMINANTS AND TIMING OF FDA WARNING LABELS

STATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE

Adaptive Design for Medical Device Development

The Clinical Research Regulatory Process

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist

Pharmaceutical Industry Research Credit Audit Guidelines

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

MEANINGFUL USE CRITERIA PHYSICIANS

TMF Reference Model. Topline results of 2014 TMF Survey #4. August 2014 Fran Ross TMF Survey Sub-team

December 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Transcription:

State of the Clinical Trials Industry A Sourcebook of Charts and Statistics 2009 SM 100 N. Washington St., Ste. 301 Boston, MA 02114 www.centerwatch.com

ix xxxv 1 41 L I S T O F F I G U R E S A N D T A B L E S F O R E W O R D I N T R O D U C T I O N 2008 in Review O N E Industry Sales Pharmaceutical Markets and Sales Top 10 Pharmaceutical Companies by Revenue Top 10 Biotech Companies by Revenue Biologics Markets and Sales Medical Device Markets and Sales Generic Drug Markets and Sales 75 T W O R&D Expenditure Research and Development Growth Rates BioPharma Research and Development Spending Spending on Development Sources of Clinical Trial Funding Industry Sponsorship of Trials National Institutes of Health (NIH) Budgets and Grant Distribution

iv 109 T H R E E Clinical Development Clinical Trial Initiations Pipeline Growth Success Rates Causes of Delays Investigational New Drug Applications (IND) Development Pipelines Development and Approval Times Numbers of Subjects in Clinical Trials Clinical Trials by Phase Clinical Trial Complexity Clinical Trial Costs per Subject Pediatric Development 157 F O U R Eye Ons and Pipelines Allergies Breast Cancer Cardiovascular Disease Eye Disorders HIV/AIDS Hormone Deficiencies Juvenile Arthritis Muscular Dystrophy Osteoporosis Ovarian Cancer Prostate Cancer Tropical Diseases 223 Sponsors F I V E CenterWatch U.S. Investigative Site Survey-Sponsors

v CenterWatch European Investigative Site Survey-Sponsors CenterWatch Latin American Investigative Site Survey-Sponsors Small Company Layoffs 257 S I X Contract Research Organizations Contract Research Organization (CRO) Market and Usage Contract Research Organization Acquisitions CenterWatch U.S. Investigative Site Survey-CROs CenterWatch European Investigative Site Survey-CROs CenterWatch Latin American Investigative Site Survey-CROs Site Management Organizations (SMO) 289 Outsourcing S E V E N Outsourcing Penetration and Expenditures CenterWatch Vendor and Outsourcing Survey Institutional Review Boards (IRB): Total and OHRP-registered Electronic Data Capture (EDC) Clinical Trial Laboratory Services Electronic Health Records (EHR) E-Diaries Market and Uptake 331 E I G H T Investigative Site Infrastructure and Operations Investigators and Study Initiations CenterWatch Survey of Physicians Employment in Clinical Research Site Productivity CenterWatch Site Financials Survey Payments to Clinical Trial Subjects CenterWatch Investigator Meeting Survey CenterWatch Training Survey

vi 383 N I N E Study Volunteers Subjects per New Drug Application (NDA) Finding Health Information Online CenterWatch Patient Experience Survey Clinical Trial Participation by Race and Gender Disease Demographics Health Care Expenditures 429 T E N U.S. Regulatory New Drug Approval (NDA) Submissions and Approvals New Molecular Entities (NME) Approvals Orphan Drug Designations and Approvals Combination Products Review and Assignments Post-marketing Commitments Investigational New Drug Applications (IND) Submissions Generic Drug Submissions and Approvals Fast Track Designations Investigational Device Exemption (IDE) Submissions and Approvals Humanitarian Device Exemptions (HDE) Premarket Notification (510(k)) Classifications Premarket Approval (PMA) Submissions FDA Inspections, Warnings, Withdrawals, Adverse Events Prescription Drug User Fee Act (PDUFA) Fees 471 Worldwide View E L E V E N Ongoing Clinical Trials Analysis of Investigators from FDA-1572 Regional Locations for Clinical Trials Canadian Clinical Trials Japanese Clinical Trials

vii Korean Clinical Trials Singapore Clinical Trials Australian Clinical Trials EU Clinical Trials Russian Clinical Trials Indian Clinical Trials Latin American Clinical Trials Country Attractiveness for Clinical Trials Global Health Care Expenditures 539 544 I N D E X A B O U T C E N T E R W A T C H